Mishra Sanjeeb Kumar, Pradhan Subrat Kumar, Pati Sanghamitra, Panda Bimal Krushna, Bhattacharya Debdutta, Sahu Sumanta Kumar, Kshatri Jaya Singh
Department of Community Medicine, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, Sambalpur, India.
Department of Biochemistry, Indian Council of Medical Research - Regional Medical Research Center, Bhubaneswar, Odisha, India.
J Family Med Prim Care. 2022 May;11(5):1883-1889. doi: 10.4103/jfmpc.jfmpc_1671_21. Epub 2022 May 14.
Since the novel SARS-CoV-2 has been detected and the ensuing pandemic, the search for a cure or prevention has been the only target of the medical fraternity. As the second wave racked havoc, vaccines seemed to be the only viable option to stop this global surge. World Health Organization (WHO) and subsequently the Government of India have issued emergency use authorization to two vaccines. Our study aims to estimate the prevalence of the anti-SARS-CoV-2 antibodies and identify predictors of antibody titers in vaccinated healthcare workers in VIMSAR, Burla.
This is a part of the ongoing, repeated cross-sectional study. Participants were enrolled well above the sample size (322) to increase precision. Two rounds of the survey were conducted and are being reported. Serum IgG antibodies against spike protein of SARS-CoV-2 were estimated using Elecsys anti-SARS-CoV-2S is an immunoassay by ECLIA-based Cobas e411 analyzer. Univariate and multivariate regression were used in statistical analysis.
Our results show that 95.1% and 99.5% of the vaccinated individuals have developed antispike protein antibodies after the first and second doses, respectively. Previous COVID-19 infection was significantly correlated with antibody production, and age was negatively correlated. No difference was reported for sex, occupation, and diabetes.
Our interim analysis report is coherent with the available literature and research regarding the high efficacy of the COVID-19 vaccine as far as seroconversion is concerned.
自新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）被发现及随之而来的大流行以来，寻找治愈方法或预防措施一直是医学界的唯一目标。随着第二波疫情肆虐，疫苗似乎是阻止这一全球疫情激增的唯一可行选择。世界卫生组织（WHO）随后印度政府已对两种疫苗发布了紧急使用授权。我们的研究旨在估计布勒拉市维姆萨尔医学科学研究所接种疫苗的医护人员中抗SARS-CoV-2抗体的流行率，并确定抗体滴度的预测因素。
这是正在进行的重复横断面研究的一部分。参与者的入选人数远高于样本量（322）以提高精确度。进行了两轮调查并进行报告。使用基于电化学发光免疫分析（ECLIA）的Cobas e411分析仪通过Elecsys抗SARS-CoV-2 S免疫测定法估计针对SARS-CoV- 的刺突蛋白的血清IgG抗体。统计分析采用单变量和多变量回归。
我们的结果表明，分别有95.1%和99.5%的接种者在接种第一剂和第二剂后产生了抗刺突蛋白抗体。既往新冠病毒感染与抗体产生显著相关，而年龄与之呈负相关。性别、职业和糖尿病方面未报告差异。
就血清转化而言，我们的中期分析报告与关于新冠病毒疫苗高效性的现有文献和研究一致。
